科研动态PubMed 摘要

Ravulizumab在HSCT-TMA儿童中显示出有利的生存获益并改善临床标志物:一项3期试验结果。

PubMed 白名单日捞 · 2026-11-13

完整摘要 · 中文译文

造血干细胞移植相关血栓性微血管病(HSCT-TMA)是一种罕见、危及生命的并发症,可导致多器官衰竭和死亡。ALXN1210-TMA-314全球、3期、开放标签、单臂试验评估了ravulizumab(一种C5抑制剂)用于治疗儿童HSCT-TMA(NCT04557735)。符合条件的参与者年龄≥28天至<18岁,在HSCT后12个月内发生HSCT-TMA,且尽管经过初始管理仍持续≥72小时。参与者在26周治疗期内接受基于体重的ravulizumab联合最佳支持治疗,随后进行26周随访期。方案定义的其主要终点为治疗期间的完全TMA缓解。关键次要终点包括各TMA缓解组分(蛋白尿、血小板和乳酸脱氢酶/裂红细胞)、总生存期(OS)和安全性。在41名入组参与者中(平均年龄7.6岁;51.2%为女性),28名(68.3%)完成治疗,24名(58.5%)完成研究。在整个治疗期间,7名(17.1%)参与者达到完全TMA缓解,22名(53.7%)达到部分TMA缓解;29名(70.7%)参与者在≥1个TMA缓解组分上取得改善。估计OS在第100天为92.6%,第26周为87.2%,第52周为73.4%。在治疗期间,研究者评估为与ravulizumab相关的严重TEAE发生率较低(3名参与者,7.3%);未发现新的安全性信号。未报告脑膜炎球菌感染。在这项针对HSCT-TMA儿童的全球3期试验中,ravulizumab治疗 使许多患者获得了极佳的总生存期(OS),并使TMA的早期实验室标志物恢复正常。试验注册:NCT04557735。

完整摘要 · 英文原文

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a rare, life-threatening complication that can lead to multiorgan failure and death. The ALXN1210-TMA-314 global, Phase 3, open-label, single-arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT-TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT-TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight-based ravulizumab plus best supportive care during the 26-week treatment period, followed by a 26-week follow-up period. The protocol-defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT-TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. TRIAL REGISTRATION: NCT04557735.

English
Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT-TMA: Results of a Phase 3 Trial.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界